Overview

Vaginal Estriol in Multiple Sclerosis

Status:
Completed

Trial end date:
2020-11-29

Target enrollment:

Participant gender:

Summary

Study to evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS. The secondary objective is to evaluate the potential role of vaginal estriol in re-myelination in RRMS patients.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Texas Tech University Health Sciences Center